SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Oct 7, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Oct. 7, 2016 · CIK: 0001604191 · Accession: 0001654954-16-002718
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212511
Letter
Re: AzurRx BioPharma, Inc.
SEC Connect
October 7, 2016
Securities and Exchange Commission
Fifth Street, N.W.
Washington, D.C.
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby join in the request of AzurRx BioPharma, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 9:30 a.m. on October 11, 2016, or as soon thereafter as practicable.
In connection with the Preliminary Prospectus distribution for the above-captioned issue, the prospective underwriters have confirmed that they are complying with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
The following information with respect to the distribution of the Preliminary Prospectus dated October 5, 2016 is furnished pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act, in connection with the request for acceleration of the effective date of the Registration Statement.
The undersigned have effected approximately the following distribution of copies of the Preliminary Prospectus, dated October 5, 2016, through the date hereof:
Preliminary Prospectus, dated October 5, 2016:
copies were distributed to prospective underwriters, institutional investors, dealers and others.
[Remainder of page intentionally left blank]
Very
truly yours,
WallachBeth
Capital, LLC
Show Raw Text
CORRESP 1 filename1.htm SEC Connect October 7, 2016 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: AzurRx BioPharma, Inc. Registration Statement on Form S-1 File No. 333-212511 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby join in the request of AzurRx BioPharma, Inc. that the effective date of the above-captioned Registration Statement be accelerated to 9:30 a.m. on October 11, 2016, or as soon thereafter as practicable. In connection with the Preliminary Prospectus distribution for the above-captioned issue, the prospective underwriters have confirmed that they are complying with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. The following information with respect to the distribution of the Preliminary Prospectus dated October 5, 2016 is furnished pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act, in connection with the request for acceleration of the effective date of the Registration Statement. The undersigned have effected approximately the following distribution of copies of the Preliminary Prospectus, dated October 5, 2016, through the date hereof: Preliminary Prospectus, dated October 5, 2016: 500 copies were distributed to prospective underwriters, institutional investors, dealers and others. [Remainder of page intentionally left blank] Very truly yours, WallachBeth Capital, LLC as Representative of the Several Underwriters By: /s/ Dan Tapia Name: Dan Tapia Title: Chief Compliance Officer Network 1 Financial Securities, Inc. as Representative of the Several Underwriters By: /s/ Damon Testaverde Name: Damon Testaverde Title: Managing Director